Explore more publications!

Djibouti Health Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Djibouti Health Journal.

Press releases published on October 31, 2025

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
IntoCell and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies
Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR
Veru to Present Two Abstracts at ObesityWeek 2025
Disc Medicine to Participate in Upcoming Investor Conferences
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
NewGen Enters Into an Innovative Digital Assets Purchase Agreement with White Lion to Acquire up to 600,000 Solana Tokens Valued at Over $110 Million
Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
Certara to Participate in Upcoming Investor Conferences
Alps Announces Closing of Business Combination with Globalink Investment Inc.
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
Vireo Growth Inc. to Release Third Quarter 2025 Results on November 12, 2025
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions